NCT01525082 2024-02-06Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine TumorsStanford UniversityPhase 2 Completed20 enrolled 15 charts
NCT04915144 2023-02-21177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsBritish Columbia Cancer AgencyPhase 2 Withdrawn
NCT00869050 2016-07-25Capecitabine and Temozolomide for Neuroendocrine CancersColumbia UniversityPhase 2 Completed41 enrolled 9 charts